JP6740250B2 - がんおよび持続性ウイルス感染を処置するための組成物および方法 - Google Patents

がんおよび持続性ウイルス感染を処置するための組成物および方法 Download PDF

Info

Publication number
JP6740250B2
JP6740250B2 JP2017556748A JP2017556748A JP6740250B2 JP 6740250 B2 JP6740250 B2 JP 6740250B2 JP 2017556748 A JP2017556748 A JP 2017556748A JP 2017556748 A JP2017556748 A JP 2017556748A JP 6740250 B2 JP6740250 B2 JP 6740250B2
Authority
JP
Japan
Prior art keywords
cells
pharmaceutical composition
group
seq
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017556748A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514558A (ja
JP2018514558A5 (enExample
Inventor
エギンク，ローラ・エル
フーバー，ジェイ・ケネス
Original Assignee
スサヴィオン バイオサイエンシーズ インコーポレイテッド
スサヴィオン バイオサイエンシーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/697,240 external-priority patent/US20150299255A1/en
Application filed by スサヴィオン バイオサイエンシーズ インコーポレイテッド, スサヴィオン バイオサイエンシーズ インコーポレイテッド filed Critical スサヴィオン バイオサイエンシーズ インコーポレイテッド
Publication of JP2018514558A publication Critical patent/JP2018514558A/ja
Publication of JP2018514558A5 publication Critical patent/JP2018514558A5/ja
Application granted granted Critical
Publication of JP6740250B2 publication Critical patent/JP6740250B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16088—Human Immunodeficiency Virus, HIV for redistribution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017556748A 2015-04-27 2015-07-08 がんおよび持続性ウイルス感染を処置するための組成物および方法 Expired - Fee Related JP6740250B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/697,240 2015-04-27
US14/697,240 US20150299255A1 (en) 2010-11-01 2015-04-27 Compositions and methods for modulating innate and adaptive immune systems
PCT/US2015/039555 WO2016175878A1 (en) 2015-04-27 2015-07-08 Compositions and methods for treating cancer and persistent viral infections

Publications (3)

Publication Number Publication Date
JP2018514558A JP2018514558A (ja) 2018-06-07
JP2018514558A5 JP2018514558A5 (enExample) 2018-10-11
JP6740250B2 true JP6740250B2 (ja) 2020-08-12

Family

ID=57198743

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017556748A Expired - Fee Related JP6740250B2 (ja) 2015-04-27 2015-07-08 がんおよび持続性ウイルス感染を処置するための組成物および方法

Country Status (5)

Country Link
US (1) US10821151B2 (enExample)
EP (1) EP3288576A4 (enExample)
JP (1) JP6740250B2 (enExample)
CA (1) CA2983666C (enExample)
WO (1) WO2016175878A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019205279A1 (en) * 2018-01-08 2020-07-30 Susavion Biosciences, Inc. Compositions and methods of treating cancer with glycomimetic peptides
CA3185526A1 (en) * 2020-07-28 2022-02-03 Laura L. Eggink Method of treatment of neutrophil-driven inflammatory pathologies
WO2023183059A1 (en) * 2022-03-24 2023-09-28 Susavion Biosciences, Inc. Method of treatment of neutrophil-driven inflammatory pathologies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
JP2005523891A (ja) 2002-01-23 2005-08-11 セル−サイ・コーポレーシヨン ペプチド構築物を用いる疾患もしくは状態の治療方法
WO2005087793A2 (en) * 2004-02-05 2005-09-22 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
US7868158B2 (en) 2004-07-19 2011-01-11 Baylor College Of Medicine Modulation of cytokine signaling regulators and applications for immunotherapy
WO2006081510A2 (en) * 2005-01-27 2006-08-03 Novartis Vaccines And Diagnostics Inc. Methods for treating renal cell carcinoma
US20060257357A1 (en) * 2005-05-10 2006-11-16 Cel-Sci Corporation Method for modulating HLA class II tumor cell surface expression with a cytokine mixture
US8496942B2 (en) * 2006-12-13 2013-07-30 Susavion Biosciences, Inc. Therapeutic peptides and uses thereof
US8460697B2 (en) 2006-12-13 2013-06-11 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
US7838497B2 (en) 2006-12-13 2010-11-23 Susavion Biosciences, Inc. Pro-angiogenic peptides
US7811995B2 (en) * 2006-12-13 2010-10-12 Susavion Biosciences, Inc. Therapeutic and diagnostic peptides
US10350260B2 (en) * 2015-04-27 2019-07-16 Susavion Biosciences, Inc. Compositions and methods for treating cancer and persistent viral infections

Also Published As

Publication number Publication date
JP2018514558A (ja) 2018-06-07
CA2983666C (en) 2021-07-27
US10821151B2 (en) 2020-11-03
EP3288576A1 (en) 2018-03-07
CA2983666A1 (en) 2016-11-03
WO2016175878A1 (en) 2016-11-03
EP3288576A4 (en) 2019-01-16
US20190328826A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
US11925693B2 (en) Polymeric nanoparticles for enhanced cancer immunotherapy
US20150299252A1 (en) Compositions and methods for modulating innate and adaptive immune systems
Su et al. New opportunities for immunomodulation of the tumour microenvironment using chemical tools
US10688165B2 (en) Medicament for use in a method of inducing or extending a cellular cytotoxic immune response
AU2021202634B2 (en) Hla-b57 open conformers
US20250312428A1 (en) Heterologous Prime Boost Vaccine
US10821151B2 (en) Compositions and methods for treating cancer and persistent viral infections
Lehner et al. The emerging role of innate immunity in protection against HIV-1 infection
Nanjundappa et al. GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC-and CD4+ T-independent CTL responses
Jost et al. Expansion of 2B4+ natural killer (NK) cells and decrease in NKp46+ NK cells in response to influenza
JP2023525084A (ja) 多発性硬化症の処置のためのペプチド及び方法
US20190282683A1 (en) Immunogenic compositions comprising sbi protein and uses thereof
US10350260B2 (en) Compositions and methods for treating cancer and persistent viral infections
JP2018514558A5 (enExample)
CN112543643A (zh) 使用可溶性cd24用于治疗获得性免疫缺陷综合征（hiv/aids）的方法
US20150299255A1 (en) Compositions and methods for modulating innate and adaptive immune systems
Ciociola et al. Peptides from the inside of the antibodies are active against infectious agents and tumours
Kabeya et al. Bovine leukaemia virus envelope peptides cause immunomodulation in BALB/c mice
Yashin et al. Cell wars fought with nanoweapons
Petley Assessment of combined vaccination and immune modulation as an anti-tumour therapy
Chibbar et al. GP120-SPECIFIC EXOSOME-TARGETED T CELL-BASED VACCINE CAPABLE OF STIMULATING DC-AND CD4+ T-INDEPENDENT CTL RESPONSES

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200303

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200706

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200722

R150 Certificate of patent or registration of utility model

Ref document number: 6740250

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees